Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02724358

Enrollment

320

Registered

2016-03-31

Start date

2012-12-31

Completion date

2015-12-31

Last updated

2016-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Notch1, Rg3, TACE

Keywords

Carcinoma, Hepatocellular, Notch1

Brief summary

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

Interventions

PROCEDURETACE

iodized oil (5ml) + Pirarubicin (20mg)

DRUGRg3

20mg, BID, maintained though Month 12.

OTHERTACE + Rg3

PROCEDUREprotective therapy

standard liver protective therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

1. Pathologically confirmed hepatocellular carcinoma. 2. High expression of Notch1 in tumor tissues.

Exclusion criteria

no pathological evidence of HCC

Design outcomes

Primary

Measure	Time frame
Overall Survival	3 years
Time to progression	3 years

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026